NCT00894062View on ClinicalTrials.gov

Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2008

Conditions
Coronary Artery Disease
Interventions
DEVICE

Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)

Zotarolimus eluting stent (ZES)

DEVICE

Everolimus eluting stent (Xience - EES)

Everolimus eluting stent (EES)

Trial Locations (3)

700-712

Dongsan Medical Center, Keimyung University, Daegu

120-752

Severance Hospital, Yonsei University, Seoul

135-710

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

Medtronic Vascular
All Listed Sponsors
collaborator

Medtronic Vascular

INDUSTRY

lead

Yonsei University

OTHER

NCT00894062 - Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent | Biotech Hunter | Biotech Hunter